Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 2 year CR?

<< Previous

Bullboard Posts

Next >>

Comment by StevenBirchon Aug 02, 2024 8:32am

236 Views

Post# 36160247

RE:RE:2 year CR?

If we do get that data early next week shouldn't we also expect some movement on BTD to be included in this update? I mean more specific info and not the 'Q3 or early Q4' that we normally get?

Eoganacht wrote: As of October 16, 2023, 42 patients had been assessed at 450 days. Those 42 patients should have now received their 2 year assessments. 14 of the 42, or 33% had a CR at 450 days. Given how durable the response is turning out, I don't think it's too much to hope that 30% of patients will be CR at 2 years. The only question is, how much post-450 day data has been sent to Theralase by the study sites.

riverrrow wrote: Have they accumulated a significant amount of 2 year CR follow up data to release next week? Will the 2 year CR be 30%.